Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy
Maria Jose Serrano 1 2 3 , Maria Carmen Garrido-Navas 4 , Juan Jose Diaz Mochon 4 5 6 , Massimo Cristofanilli 7 , Ignacio Gil-Bazo 8 , Patrick Pauwels 9 , Umberto Malapelle 10 , Alessandro Russo 11 , Jose A Lorente 4 12 , Antonio J Ruiz-Rodriguez 13 , Luis G Paz-Ares 14 , Eduardo Vilar 15 , Luis E Raez 16 , Andres F Cardona 17 18 19 , Christian Rolfo, International Society of Liquid Biopsy
Despite major therapeutic progress, most advanced solid tumors are still incurable. Cancer interception is the active way to combat cancer onset, and development of this approach within high-risk populations seems a logical first step.
Until now, strategies for the identification of high-risk subjects have been based on low-sensitivity and low-specificity assays. However, new liquid biopsy assays, "the Rosetta Stone of the new biomedicine era," with the ability to identify circulating biomarkers with unprecedented sensitivity, promise to revolutionize cancer management.
This review focuses on novel liquid biopsy approaches and the applications to cancer interception. Cancer interception involves the identification of biomarkers associated with developing cancer, and includes genetic and epigenetic alterations, as well as circulating tumor cells and circulating epithelial cells in individuals at risk, and the implementation of therapeutic strategies to prevent the beginning of cancer and to stop its development.
Large prospective studies are needed to confirm the potential role of liquid biopsy for early detection of precancer lesions and tumors.
CITA DEL ARTÍCULO Cancer Discov. 2020 Oct 9. doi: 10.1158/2159-8290.CD-20-0466